Q&A: Ireland’s Leo Varadkar on Brexit, Trump and Keeping Ireland ‘At the Center of the World’

Leo Varadkar is quite a few firsts rolled into one. At 38, he is his country’s youngest ever Taoiseach, or Prime Minister. He’s also the first from an ethnic minority background, and the first to have come out as gay. His appointment in June is symbolic of the shift in social values in the once staunchly Catholic country.

Click HERE to read more.

Anti-American countries get far more green cards than than the Irish do
By Niall O’Dowd
IrishCentral.com

The numbers from the annual diversity lottery visa are out and they make this Irishman’s blood boil. We’ve been had as a nation, as one of the founder countries who helped create this great republic.

What the 1965 immigration reform act has done for the Irish is made new Irish immigrants as scarce as hen’s teeth.

And yes I know, it was Senator Edward Kennedy who played the major role in drafting that law. He tried to reverse its anti-Irish outcome before he died, but it was too late.

Now comes just the latest example. Each year 50,000 US Green Cards are allocated among 35 countries who are disadvantaged by current immigration law.

Read More

Amicus Therapeutics’s stock soars on heavy volume after FDA clears NDA submission for Fabry disease treatment

Shares of Amicus Therapeutics Inc. FOLD, -2.24% shot up 40% toward a 22-month high in active premarket trade Tuesday, after the biotechnology company said the Food and Drug Administration cleared the company to submit a new drug application for its Fabry disease treatment. Volume approached 600,000 shares about 90 minutes before the open, making the stock the most actively traded in the premarket session. The company said it plans to submit an NDA for oral precision medicine migalastat in the fourth quarter of 2017. “We are moving ahead expeditiously with our NDA submission and accelerating the U.S. pathway for migalastat,” said Chief Executive John Crowley. “Today is a seminal moment in the development of migalastat and a testament to the dedication and perseverance of the patients, physicians and employees who have worked so hard on the development of this precision medicine.” The stock had doubled year to date through Monday, while the iShares Nasdaq Biotechnology ETF IBB, +0.25% has climbed 17% and the S&P 500 SPX, +0.62% has gained 8.4%.

 

Welcome new Irish Chamber members!
Be sure to look out for new members at upcoming events. They will have maroon ribbons on their name tags.

Individual Members

Robert F. Hart, CFP®, Bernstein Private Wealth Management
Janice K. Marini, Thomas Jefferson University
James Harbeson, Bank of America
Thomas Morrissey, Univest Insurance, Inc. 

Mid-Size Firm Members

– U.S. Trust, William Meagher, Michael P. Terry, Catherine Adams Baldry
The Graham Company, Andrew Corrigan, Kevin Funston, Christopher Whitney

Breaking News: Almac Discovery is Granted Orphan Drug Designation for ALM201 Programme in Ovarian Cancer 

Craigavon, N.I., UK, 3 Jul 2017 Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its drug candidate ALM201 in the treatment of ovarian cancer.

ALM201 is a therapeutic peptide developed to mimic some of the properties of the naturally occurring protein FKBPL. The development of ALM201 by Almac Discovery builds upon initial research work by Professor Tracy Robson who has shown that FKBPL is a naturally secreted protein with effects on a number of important tumour biology processes including cancer stem cells and angiogenesis.

Read More